QEII Health Sciences Center, Halifax, Nova Scotia, Canada.
QEII Health Sciences Center, Halifax, Nova Scotia, Canada.
Ann Emerg Med. 2019 Apr;73(4):382-392. doi: 10.1016/j.annemergmed.2018.09.001. Epub 2018 Oct 26.
Lack of oral anticoagulation prescription in the emergency department (ED) has been identified as a care gap in atrial fibrillation patients. This study seeks to determine whether the use of a tool kit for emergency physicians with a follow-up community-based atrial fibrillation clinic resulted in greater oral anticoagulation prescription at ED discharge than usual care.
This was a before-after study in 5 Canadian EDs in 3 cities. Patients who presented to the ED with atrial fibrillation were eligible for inclusion. The before phase (1) was retrospective; 2 after phases (2 and 3) were prospective: phase 2 used an oral anticoagulation prescription tool for emergency physicians and patient education materials, whereas phase 3 used the same prescription tool, patient materials, atrial fibrillation educational session, and follow-up in an atrial fibrillation clinic. Each phase was 1 year long. The primary outcome was the rate of new oral anticoagulation prescription at ED discharge for patients who were oral anticoagulation eligible and not receiving oral anticoagulation at presentation.
A total of 631 patients were included. Mean age was 69 years (SD 14 years), 47.4% were women, and 69.6% of patients had a CHADS score greater than or equal to 1. The rate of new oral anticoagulation prescription in phase 1 was 15.8% compared with 54.1% and 47.2%, in phases 2 and 3, respectively. After multivariable adjustment, the odds ratio for new oral anticoagulation prescription was 8.03 (95% confidence interval 3.52 to 18.29) for phase 3 versus 1. The 6-month rate of oral anticoagulation use was numerically but not significantly higher in phase 3 compared with phase 2 (71.6% versus 79.4%; adjusted odds ratio 2.30; 95% confidence interval 0.89 to 5.96). The rate of major bleeding at 6 months was 0%, 0.8%, and 1% in phases 1, 2, and 3, respectively.
An oral anticoagulation prescription tool was associated with an increase in new oral anticoagulation prescription in the ED, irrespective of whether an atrial fibrillation clinic follow-up was scheduled. The use of an atrial fibrillation clinic was associated with a trend to a higher rate of oral anticoagulation at 6-month follow-up.
在房颤患者中,急诊科(ED)缺乏口服抗凝剂处方已被确定为护理空白。本研究旨在确定在 ED 出院时,使用一种为急诊医生配备的工具包并结合社区基础房颤诊所的后续治疗,是否会比常规护理更能增加口服抗凝剂的处方。
这是在加拿大 3 个城市的 5 家 ED 进行的一项前后对照研究。符合纳入标准的患者为 ED 就诊的房颤患者。前一阶段(1)为回顾性;两个后续阶段(2 和 3)为前瞻性:阶段 2 为急诊医生使用口服抗凝剂处方工具和患者教育材料;阶段 3 则使用相同的处方工具、患者材料、房颤教育课程以及房颤诊所的后续治疗。每个阶段持续 1 年。主要结局是新口服抗凝剂处方的比率,对于有口服抗凝剂适应证且就诊时未接受口服抗凝剂的患者。
共纳入 631 例患者。平均年龄为 69 岁(SD 14 岁),47.4%为女性,69.6%的患者 CHADS 评分≥1。第 1 阶段新口服抗凝剂处方率为 15.8%,第 2 和第 3 阶段分别为 54.1%和 47.2%。多变量调整后,第 3 阶段与第 1 阶段相比,新口服抗凝剂处方的比值比为 8.03(95%置信区间 3.52 至 18.29)。与第 2 阶段相比,第 3 阶段 6 个月的口服抗凝剂使用率虽然数值上无显著差异,但略有升高(71.6%比 79.4%;调整后的比值比 2.30;95%置信区间 0.89 至 5.96)。第 1、2 和 3 阶段 6 个月时主要出血的发生率分别为 0%、0.8%和 1%。
口服抗凝剂处方工具与 ED 中新的口服抗凝剂处方的增加有关,无论是否安排房颤诊所的随访。使用房颤诊所与 6 个月随访时口服抗凝剂使用率升高的趋势有关。